Hengrui Pharma Obtains Priority Review for Breast Cancer Drug

Jiangsu Hengrui Pharmaceuticals (SHA:600276) subsidiary Suzhou Suncadia received acceptance and priority review designation from China's medical products administrator for Recurcept as a treatment for HER2-low metastatic breast cancer. Recurcept, already approved for HER2-mutant non-small cell lung cancer and HER2-positive breast cancer, has now received 11 breakthrough therapy designations, according to a Thursday filing with the Shanghai bourse.